PMID: 22552461May 4, 2012Paper

Antifungal susceptibilities of Cryptococcus species complex isolates from AIDS and non-AIDS patients in Southeast China

The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases
Meng LiLixing Weng

Abstract

Cryptococcus spp. are common causes of mycoses in immunocompromised patients. To determine the drug susceptibilities of clinical Cryptococcus spp. isolates, the characteristics of 61 clinical Cryptococcus spp. complex isolates and their antifungal susceptibilities were investigated, including 52 C. neoformans and 9 C. gattii isolates collected at Shanghai between 1993 and 2009. Antifungal susceptibility of clinical isolates to amphotericin B, fluconazole, itraconazole, and flucytosine were determined by the microdilution method M27-A2 and the ATB FUNGUS 3 kit. The 90% minimum inhibitory concentration (MIC90) and susceptibility ranges were as follows: 1 (0.0625-1) µg/mL for amphotericin B, 4 (0.125-16) µg/ mL for fluconazole, 0.25 (0.0313-4) µg/mL for itraconazole, and 4 (0.125-8) µg/mL for flucytosine. Fluconazole, itraconazole, and flucytosine have excellent in vitro activity against all tested clinical Cryptococcus spp., and we also found a high rate of tolerance to amphotericin B (MICs ranging from 0.55-1 µg/mL). Furthermore, C. neoformans isolates from acquired immune deficiency syndrome (AIDS) patients were less susceptible to fluconazole and flucytosine than those from non-AIDS patients. These data suggest that use of amp...Continue Reading

References

Mar 24, 2000·Diagnostic Microbiology and Infectious Disease·Y C ChenW C Hsieh
Apr 20, 2004·AIDS·Françoise DromerUNKNOWN French Cryptococcosis Study Group
May 14, 2004·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J ChandenierD Richard-Lenoble
Jul 16, 2004·The Journal of Antimicrobial Chemotherapy·Borann SarYves Buisson
Jul 14, 2005·Medical Mycology·Zhirong YaoRengui Chen
Nov 12, 2005·The Journal of Antimicrobial Chemotherapy·Alexander PerkinsManuel Cuenca-Estrella
May 16, 2006·FEMS Yeast Research·Kyung J Kwon-Chung, Ashok Varma
Sep 20, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Juliette MorganUNKNOWN Gauteng Cryptococcal Surveillance Initiative Group
Feb 22, 2007·FEMS Yeast Research·Ana Marisa Fusco AlmeidaUNKNOWN Laboratory Group on Cryptococcosis
Jun 19, 2008·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A Gomez-LopezM Cuenca-Estrella
Apr 7, 2009·Diagnostic Microbiology and Infectious Disease·Mara C S M PappalardoMarcia S C Melhem
Dec 17, 2009·Journal of Clinical Microbiology·Naureen IqbalUNKNOWN Cryptococcus gattii Public Health Working Group

❮ Previous
Next ❯

Citations

Mar 13, 2014·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Melyssa NegriErika Seki Kioshima
Feb 28, 2015·Fungal Genetics and Biology : FG & B·Ferry HagenTeun Boekhout
Jan 23, 2020·Genes·Himeshi SamarasingheTimothy Y James
Jan 8, 2017·The Journal of Biological Chemistry·Jessica L ChittyJames A Fraser

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.